Appetite and Energy Regulation Studies Both compounds stimulate significant research interest in appetite signaling and energy homeostasis regulation pathways
placebo) Adverse events were consistent with those observed in other clinical trials for other incretins, the most common among participants treated with retatrutide (9 mg and 12 mg, respectively) being nausea (38.1% and 43.2% vs 10.7% with placebo), diarrhea (34.7% and 33.1% vs 13.4% with placebo), constipation (21.8% and 25.0% vs 8.7% with placebo), vomiting (20.4% and 20.9% vs 0.0% with placebo), and decreased appetite (19.0% and 18.2% vs 9.4% with placebo)
Significant improvements were observed in inflammation markers, weight, and cholesterol levels over 12 months of treatment
The side effect profile of DPP-4 inhibitors is favorable, there are few treatment-limiting adverse effects and DPP-4 inhibitors have shown cardiovascular safety
However, their prolonged and widespread application has led to serious concerns regarding antimicrobial resistance and drug residues, posing significant threats to both livestock product quality and public health [1]
